Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

  • ID: 4576095
  • Report
  • 94 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bioleaders Corp
  • CEL-SCI Corp
  • Genexine Inc
  • IRX Therapeutics Inc
  • PDS Biotechnology Corp
  • Transgene SA
  • MORE
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights:

This latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 11, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bioleaders Corp
  • CEL-SCI Corp
  • Genexine Inc
  • IRX Therapeutics Inc
  • PDS Biotechnology Corp
  • Transgene SA
  • MORE
Introduction

Report Coverage

Cervical Intraepithelial Neoplasia (CIN) - Overview

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development

Bioleaders Corp

CEL-SCI Corp

Genexine Inc

Inovio Pharmaceuticals Inc

IRX Therapeutics Inc

PDS Biotechnology Corp

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

THEVAX Genetics Vaccine USA Inc

Transgene SA

Vaccibody AS

Vaxart Inc

Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles

ABI-1968 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXI-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IRX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multikine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-721689 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDS-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVGV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E7 for HPV Associated Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-1016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products

Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones

Featured News & Press Releases

Feb 14, 2018: IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3

Dec 12, 2017: Vaccibody Announces Finalization of the Recruitment in the Phase IIa Part of Its Study With VB10.16 Immunotherapy for Patients With HPV16 Induced High Grade Lesions of the Cervix

Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy

Jun 21, 2017: Vaccibody Announces Positive Results From the 12-month Analysis of the Phase I Part of the Clinical Trial VB C-01 in Patients With High-grade Cervical Dysplasia

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

Mar 23, 2017: Vaccibody Announces Vaccination Of First Patient In Its Phase IIA Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix

Mar 02, 2017: Vaccibody Announces Approval Of Amendment Of IMPD Allowing To Start Of Expansion Phase In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed

Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet

Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe

Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe

Jan 26, 2015: TheVax Genetics Vaccine Announces TVGV-1 Update

Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Bioleaders Corp, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by IRX Therapeutics Inc, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaxart Inc, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2018

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bioleaders Corp
  • CEL-SCI Corp
  • Genexine Inc
  • Inovio Pharmaceuticals Inc
  • IRX Therapeutics Inc
  • PDS Biotechnology Corp
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • Vaccibody AS
  • Vaxart Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll